TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors
15 avr. 2020 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day
03 avr. 2020 07h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
30 mars 2020 06h45 HE
|
TCR2 Therapeutics
Company initiated Phase 1/2 clinical trial for TC-110, its lead hematological malignancy candidateInterim update from Phase 1 portion of TC-210 Phase 1/2 trial anticipated in 2Q20 and Phase 1/2 trial...
TCR² Therapeutics to Participate in Two Upcoming Conferences in February
18 févr. 2020 07h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics to Present an Allogeneic Construct at the Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and Beyond
03 févr. 2020 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
07 janv. 2020 07h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 nov. 2019 07h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer
09 oct. 2019 06h30 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics to Present at the Cantor Global Healthcare Conference
27 sept. 2019 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
30 août 2019 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...